Terrestrial Bio, Inc.

WOBURN, MA · Founded 2012 · Biotech · Private

Oral delivery system for GLP-1 peptide therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · terrestrialbio.com

Sector: Biotech
Headquarters: WOBURN, MA
Founded: 2012
Latest Form D: $57.3M, Mar 2026
Total capital: $128M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $128M; 11 Form D · last Mar 2026; 7 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 6 pending · first 2025; Rank in peer group#339 of 1449

Capital timeline

Latest events

Mar 2026Private capital raisedForm D · SEC · 11th filing$57.3M
Sep 2025Private capital raisedForm D · SEC · 10th filing$7.9M
Feb 2025Private capital raisedForm D · SEC · 9th filing$8.4M
May 2024Private capital raisedForm D · SEC · 8th filing$10.8M
Jul 2023Private capital raisedForm D · SEC · 7th filing$9.1M
Oct 2022Private capital raisedForm D · SEC · 6th filing$2M
May 2021Private capital raisedForm D · SEC · 5th filing$25.3M
Mar 2021Private capital raisedForm D · SEC · 4th filing$2M
Feb 2019Private capital raisedForm D · SEC · 3rd filing$3.6M
Jan 2017Private capital raisedForm D · SEC · 2nd filing$863K
May 2013Private capital raisedForm D · SEC · 1st filing$1.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#339 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Ann DeWittDirectorNamed in SEC Form D filings
Fenel EloiDirectorNamed in SEC Form D filings
Kathryn KousdaExecutive Officer, DirectorNamed in SEC Form D filings
Linda TusseyExecutive OfficerNamed in SEC Form D filings
Livio ValentiExecutive OfficerNamed in SEC Form D filings
Peter KolchinskyDirectorNamed in SEC Form D filings

Show all 7 people

Rachel ShaExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 9

Jun 9, 2026GrantedApplicator And Microneedle Array Patch Delivery SystemUSPTOUS 12,649,053
May 26, 2026GrantedMicroneedle Array Patches (maps), Systems, And Methods For Manufacturing And Using SameUSPTOUS 12,636,250
Mar 5, 2026PendingApplicator For A Microneedle Array Patch Delivery SystemUSPTOApplication 19320152

Show all 9 patent records

Applicator And Microneedle Array Patch Delivery SystemJun 9, 2026 · US 12,649,053Granted
Microneedle Array Patches (maps), Systems, And Methods For Manufacturing And Using SameMay 26, 2026 · US 12,636,250Granted
Applicator For A Microneedle Array Patch Delivery SystemMar 5, 2026 · Application 19320152Pending
Applicator For Medicament PatchDec 25, 2025 · Application 18878409Pending
Applicator For A Microneedle Array Patch Delivery SystemOct 7, 2025 · US 12,434,040Granted
Applicator For Medicament PatchDec 12, 2024 · Application 18806128Pending
Applicator for Medicament PatchApplication 63355301Pending
An Applicator And Microneedle Array Patch Delivery SystemApplication PCTUS2025060139Pending
An Applicator For A Microneedle Array Patch Delivery SystemApplication PCTUS2025060143Pending

Electra TherapeuticsSimilar federal contract value in Biotech · null in contracts
Caribou BiosciencesSimilar federal contract value in Biotech · null in contracts
Sirnaomics, Inc.Similar federal contract value in Biotech · null in contracts
iTeos TherapeuticsSimilar federal contract value in Biotech · null in contracts
Star TherapeuticsSimilar federal contract value in Biotech · null in contracts
NextPoint TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.